GSK beats sales estimate and ups EPS guidance

27 October 2021
glaxo_gsk_glaxosmithkline_big

UK drugmaker GlaxoSmithKline (LSE: GSK) reported sales for the third quarter of £9.08 billion ($12.47), an increase of 5% on the same period in 2020 and ahead of the £8.7 billion predicted by analysts.

Pharmaceutical revenue was up 5% at £4.4 billion, with sales from the oncology, immuno-inflammation and respiratory product areas all up by more than 30%. Sales from GSK’s Vaccines unit jumped by 7.7% to £2.2 billion.

"Double-digit sales growth in Pharmaceuticals and Vaccines"The Consumer Healthcare division, which will split from GSK in a de-merger planned for mid-2022, delivered quarterly sales of £2.5 billion, a 3% rise.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical